12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dipraglurant-IR: Phase IIa data

Top-line data from a double-blind, placebo-controlled, international Phase IIa trial in 76 patients with moderate to severe PD-LID showed that oral dipraglurant-IR plus levodopa was well tolerated and met the primary safety endpoint with no changes in liver function tests reported. Additionally, the incidence of adverse events was similar in patients receiving dipraglurant and placebo (88.5% vs. 75%). On exploratory endpoints, dipraglurant significantly reduced peak mAIMS scores on...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >